Update shared on19 Sep 2025
Fair value Increased 5.46%The upward revision in Eckert & Ziegler’s price target reflects modest improvements in both future P/E and net profit margin, resulting in a new consensus fair value of €22.85.
What's in the News
- Confirmed 2025 earnings guidance with expected sales of approximately €320 million and EBIT before special items of about €78 million.
- Announced a 3-for-1 stock split effective August 13, 2025.
- Entered a Master Service Agreement with Archeus Technologies for contract manufacturing of ART-101 to support a Phase 1 clinical trial in the US, with manufacturing at the Boston GMP facility.
Valuation Changes
Summary of Valuation Changes for Eckert & Ziegler
- The Consensus Analyst Price Target has risen from €21.67 to €22.85.
- The Future P/E for Eckert & Ziegler has risen slightly from 27.72x to 28.50x.
- The Net Profit Margin for Eckert & Ziegler has risen slightly from 15.24% to 15.67%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.